`
`
`
`DEPARTMENT OF HEALTH AND HUMAN SERVICES
`
`
`
`
`
`
` NDA 022341/S-020
`
`
`
`
`
`
`
`
`
`
`Food and Drug Administration
`
`
` Silver Spring MD 20993
`
`SUPPLEMENT APPROVAL
`
`
` Novo Nordisk, Inc.
`
` Attention: Robert B. Clark
`
`
` VP Regulatory Affairs
` P.O. Box 846
`
`
`
` 800 Scudders Mill Road
`
` Plainsboro, NJ 08536
`
`
`
`
`Dear Mr. Clark:
`
`
`
`
`
`
`
`Please refer to your Supplemental New Drug Application (sNDA) dated and received
`
`
`
`May 2, 2013, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act
`
`(FDCA) for Victoza (liraglutide [rNDA origin] injection).
`
`
`
`
`
`This “Prior Approval” supplemental new drug application proposes revisions to the Victoza
`
`Patient Instructions for Use (IFU).
`
`
`
`
`
`We have completed our review of this supplemental application, as amended. It is approved,
`
`
`
`effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling
`
`text.
`
` CONTENT OF LABELING
`
`
`
`As soon as possible, but no later than 14 days from the date of this letter, submit the content of
`
`
`
`
`
`labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA
`
`automated drug registration and listing system (eLIST), as described at
`
`
`http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content
`of labeling must be identical to the enclosed labeling, with the addition of any labeling changes
`
`
`
`in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes
`
`not included in the enclosed labeling.
`
`
`Information on submitting SPL files using eList may be found in the guidance for industry titled
`
`
`
`“SPL Standard for Content of Labeling Technical Qs and As at
`
`
`
`http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/U
`CM072392.pdf
`
`
`The SPL will be accessible from publicly available labeling repositories.
`
`
`
`
`
`
`Reference ID: 3324290
`
`
`
`
`
`
`
` NDA 022341/S-020
`
` Page 2
`
`
`
` Also within 14 days, amend all pending supplemental applications that includes labeling changes
`
` for this NDA, including CBE supplements for which FDA has not yet issued an action letter,
`
`
` with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the
`
`
`
`
`
`changes approved in this supplemental application, as well as annual reportable changes and
`annotate each change. To facilitate review of your submission, provide a highlighted or marked-
`
`
`up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy
`
`should provide appropriate annotations, including supplement number(s) and annual report
`
`
`
`
`
`
`date(s).
`
`
` REPORTING REQUIREMENTS
`
`We remind you that you must comply with reporting requirements for an approved NDA
`
`
`
`(21 CFR 314.80 and 314.81).
`
`
`
`If you have any questions, please call Pooja Dharia, Pharm.D., Regulatory Project Manager, at
`
`
`
`(301) 796-5332.
`
`
`
`
`
`
`Sincerely,
`
`
`{See appended electronic signature page}
`
`
`Amy G. Egan, M.D., MPH
`
`Deputy Director for Safety
`
`
`Division of Metabolism and Endocrinology Products
`
`Office of Drug Evaluation II
`
`
`Center for Drug Evaluation and Research
`
`
`
`ENCLOSURE: Content of Labeling
`
`
`
`Package Insert (approved April 16, 2013 with S-018)
`
`
`
`Medication Guide (approved April 6, 2012 with S-013)
`
`Patient Instructions for Use
`
`
`
`
`Reference ID: 3324290
`
`
`
`---------------------------------------------------------------------------------------------------------
`This is a representation of an electronic record that was signed
`electronically and this page is the manifestation of the electronic
`signature.
`---------------------------------------------------------------------------------------------------------
`/s/
`----------------------------------------------------
`
`POOJA DHARIA
`06/13/2013
`
`Reference ID: 3324290
`
`